Read out the clinical endpoints of the Phase 3 chronic low back pain trial of rexlemestrocel-L

Deadline not yet reached (430 days left)

Announced: 13 Oct 2026
Due: 31 Dec 2027

Deadline
Met
Late
Not met
Today

What the company said

“We look forward to reading out the trial's clinical endpoints during the second half of the 2027 calendar year.”

SourceMesoblast Ltd. Form 6-K press release, 2026-10-13
Archived copyWayback Machine snapshot
FilingSEC filing index
Deadline as statedduring the second half of the 2027 calendar year
Deadline used31 Dec 2027, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-MESO-010750
Cite as https://keptindex.org/c/KI-C-2026-MESO-010750/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2027.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout late
Indicative materiality: High rules
Action: Read
Deliverable: Clinical endpoint readout of rexlemestrocel-L Phase 3 CLBP trial
In the company’s control: Medium
Specificity: High

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Mesoblast Ltd.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-MESO-010750 · Corrections policy